cardio-oncology, echo strain assessment, echoinsight, epsilon
cardio-oncology, echo strain assessment, GE echo, GE ultrasound, strain imaging
cardio-oncology, Toshiba echo, toshiba ultrasound

Cardio-oncology is an emerging field that combines the expertise of both cardiology and oncology to assess and treat cancer patients for the second leading cause of death among cancer survivors — cardiovascular disease brought on by their treatments. Specific types of chemotherapy and chest-directed radiation therapy are known to cause cardiac dysfunction, mainly due to cardiotoxicity — the symptoms of which may not present until months or even years after cancer treatment. 

The prostate is a tiny organ surrounded by critical structures. When radiation treatments deliver dose to any of these structures, it can sometimes lead to problems such as erectile dysfunction and bladder or rectal irritation.

A new approach for identifying the best computed tomography (CT) imaging methods for lung cancer and chronic obstructive pulmonary disease (COPD) was recently launched by the Prevent Cancer Foundation and advisors to its annual Quantitative Imaging Workshop.

Researchers in the United Kingdom have successfully shown for the first time that breast cancer patients can be trained to achieve single prolonged breath-holds of over five minutes.

Breast Microseed Treatment

Concure Oncology/Breast Microseed Inc. announced the launch of its one-time, one-hour radiation treatment option for early-stage breast cancer.

Using a new imaging agent that binds to tau protein and makes it visible in positron emission tomography (PET) scans, scientists at Washington University School of Medicine in St. Louis have shown that measures of tau are better markers of the cognitive decline characteristic of Alzheimer’s than measures of amyloid beta seen in PET scans.

Winthrop-University Hospital, Mineola, N.Y., recently added a universal viewer to its Carestream Vue for Clinical Collaboration Platform.

May 11, 2016 — ITM (Isotopen Technologien München AG), a specialized radiopharmaceutical company, announced that the Committee for Medicinal Products for Human Use (CHMP) , has adopted a positive opinion on the Marketing Authorization Application (MAA) for EndolucinBeta. The radiopharmaceutical is a product of ITM´s subsidiary ITG Isotope Technologies Garching GmbH. CHMP is part of the European Medicines Agency (EMA).

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now